Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Oxybutynin Articles

Overactive bladder gel gets FDA nod

9 December 2011

Watson presents data on Ph III urology products

2 June 2008

First launch for UCB's Kentera for OAB

25 April 2005

Watson Pharma's EPS tops analysts' hopes

21 February 2005

Watson lowers 2nd-qtr forecasts; refocuses strategy

5 July 2004

Watson's Oxytrol OKed in Canada

5 July 2004

Watson's oxybutynin patch gets EU OK

28 June 2004

Paladin signs licensing accord with Watson

19 January 2004

UCB confident on Pharma's future and ups its forecasts for 2003

5 January 2004

Watson licenses novel product to UCB

6 October 2003

Oxytrol accepted for review in Canada

2 June 2003

Watson signs sales force deal with Ventiv

24 March 2003

Watson's incontinence patch cleared by US FDA

3 March 2003

Watson gets US OK on new use for Alora

15 April 2002

Watson sees 2001 revenues, income rise

25 February 2002

Positive results for Watson's Oxytrol

16 August 2001

Watson files NDA for oxybutynin patch

1 May 2001

Japanese Collaboration To Market Oxybutynin Patch

16 October 1997

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS